The Intrauterine Device: How to Deploy This Strategy in the Molecular World?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39254401.
- Also identified by DOI 10.1158/1078-0432.CCR-24-2034 and PMC identifier 11567785.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance. See related article by Bowen et al., p. 5073.
Medical subject headings
- Endometrial Neoplasms
- Fertility Preservation
- Intrauterine Devices
- Levonorgestrel